Daclatasvir (USAN) (formerly BMS-790052, trade name Daklinza) is a drug for the treatment of hepatitis C (HCV). It is was developed by Bristol-Myers Squibb and was approved in Europe on 22 August 2014. Daclatasvir inhibits the HCV nonstructural protein NS5A. Recent research suggests that it targets two steps of the viral replication process, enabl...
Found on
http://en.wikipedia.org/wiki/Daclatasvir
formerly BMS-790052) is an experimental drug candidate for the treatment of hepatitis C. It is being developed by Bristol-Myers Squibb. Daclatasvir's mechanism of action involves inhibition of the HCV structural protein NS5A. Recent research suggests that it targets two steps of the viral replication process, enabling rapid decline of HCV RNA.
Found on
http://www.encyclo.co.uk/local/22225
No exact match found.
